Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONY: HTD1801 vs Dapagliflozin in Type 2 Diabetes
NCT06415773Phase 3Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of berberine ursodeoxycholate in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by HighTide Therapeutics, Inc. Primary endpoint: Mean change in HbA1c at 24 weeks. Started Jun 2024; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06415773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415773.